Expanding our opportunities for success

In 2017, we entered into a worldwide agreement with Janssen Biotech, Inc. to co-develop and commercialize PTG-200 for all indications, including inflammatory bowel disease (IBD). The scope of the collaboration was expanded in 2019 to additionally support efforts towards second-generation IL-23 receptor antagonists. To date, the ongoing collaboration has resulted in three development candidates targeted as oral IL-23 receptor antagonists for multiple disease indications including IBD. PTG-200 (JNJ-67864238) is in a Phase 2 study in patients with Crohn’s disease. PN-235 (JNJ-77242113) and PN-232 (JNJ-75105186) are new oral IL-23 receptor antagonism-based development candidates, and PN-235 entered Phase 1 studies in Q4 2020.

We are open to additional collaborative opportunities involving our other pipeline product candidates. If interested, you can get in touch here.